Approximately half of PCV eyes with complete polypoidal regression under aflibercept experience recurrence within 2 years when managed with PRN regimens.
Visual acuity decline and new hemorrhages occur in a subset of recurrent cases, underscoring the need for vigilant monitoring.
Baseline presence of massive subretinal hemorrhage may predict lower recurrence risk, while leakage without hemorrhage may indicate higher recurrence potential.
Posttreatment OCT biomarkers offer promising stratification tools for tailoring continuation versus deferral of anti-VEGF therapy in PCV.
